Trial of Dasatinib in Advanced Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00464620
Recruitment Status : Active, not recruiting
First Posted : April 23, 2007
Last Update Posted : March 22, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration

April 20, 2007
April 23, 2007
March 22, 2017
May 2007
December 2016   (Final data collection date for primary outcome measure)
Evaluation of all lesions for progression or response will be made at 2-month intervals for the first 6 months and then every 3 months thereafter [ Time Frame: every 2 months ]
Evaluation of all lesions for progression or response will be made at 2-month intervals for the first 6 months and then every 3 months thereafter.
Complete list of historical versions of study NCT00464620 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Trial of Dasatinib in Advanced Sarcomas
A Phase II Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.

Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment.

A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment.

Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur.

Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Rhabdomyosarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Chondrosarcoma
  • Sarcoma, Ewing's
  • Sarcoma, Alveolar Soft Part
  • Chordoma
  • Epithelioid Sarcoma
  • Giant Cell Tumor of Bone
  • Hemangiopericytoma
  • Gastrointestinal Stromal Tumor (GIST)
Drug: Dasatinib
oral agent, continuous dosing, Cycles = 28 days
Experimental: Dasatinib, 70 mg, twice daily
Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Intervention: Drug: Dasatinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
May 2017
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Unresectable, recurrent, or metastatic histologically-confirmed soft tissue or bone sarcoma of one of the following subtypes:

    • Leiomyosarcoma --* NO LONGER ELIGIBLE*
    • Liposarcoma--* NO LONGER ELIGIBLE*
    • Malignant fibrous histiocytoma (MFH)/pleomorphic undifferentiated sarcoma--* NO LONGER ELIGIBLE*
    • Rhabdomyosarcoma --* NO LONGER ELIGIBLE*
    • Malignant peripheral nerve sheath tumor (MPNST) --* NO LONGER ELIGIBLE*
    • Osteosarcoma (skeletal or extraosseous)--* NO LONGER ELIGIBLE*
    • Ewing's --* NO LONGER ELIGIBLE*
    • Chondrosarcoma
    • Alveolar soft part sarcoma
    • Chordoma
    • Epithelioid sarcoma
    • Giant cell tumor of bone
    • Hemangiopericytoma/solitary fibrous tumor
    • Gastrointestinal Stromal Tumor (GIST) --* NO LONGER ELIGIBLE*
  2. Documentation that subjects with leiomyosarcoma, liposarcoma, osteosarcoma, Ewing's, MPNST, rhabdomyosarcoma or MFH have received, not been eligible for or refused at least one prior chemotherapy regimen before participation in the dasatinib study. Subjects with GIST must have received or been intolerant to imatinib; prior treatment with other agents including sunitinib is not required.Neoadjuvant/adjuvant chemotherapy qualifies as prior therapy.
  3. Subjects must have unidimensionally measurable lesion(s) either by x-ray, computed tomography (CT), magnetic resonance imaging (MRI) or physical examination documented within 30 days prior to registration.
  4. Prior radiation will be allowed. More than two weeks should have elapsed since the administration of the last fraction of radiation therapy, and subjects must have recovered from grade 2 or higher associated toxicities. Measurable lesions, which are selected as target lesions, must be outside previously radiated fields or have documented progression no sooner than 6 weeks after completion of radiation.
  5. More than 2 weeks must have elapsed since the subject has received any prior systemic chemotherapy (6 weeks for mitomycin C), and the patient should have recovered from toxicities to the baseline prior to the last course of chemotherapy.
  6. Adequate hematologic function within 14 days prior to registration.
  7. PT (or INR) and PTT ≤ 1.5 times the institutional ULN within 14 days prior to registration.
  8. Serum creatinine ≤ 2.0 times the institutional ULN within 14 days prior to registration.
  9. Serum magnesium, potassium and adjusted (or ionized) calcium ≥ the institutional LLN. (Supplementation of electrolytes prior to screening is allowed).
  10. Left ventricular ejection fraction ≥ 45% measured by echocardiogram or multiple gated acquisition (MUGA) within 30 days prior to registration (but must be performed after the last dose of an anthracycline) for subjects who have received an anthracycline (e.g. doxorubicin, epirubicin) or have a medical history of cardiac disease. The measurement of left ventricular ejection fraction is not required of subjects whom have not received cardiotoxic chemotherapy (e.g. anthracycline) and do not have a medical history of cardiac disease.
  11. Sexually active women and men of childbearing potential must agree to use an effective method of birth control during the course of the study and for up to 3 months following the last dose of the study drug, in a manner such that risk of pregnancy is minimized. Surgical sterilization, intrauterine device or barrier method (e.g. condom and/or diaphragm with spermicidal agents) are acceptable forms of birth control.
  12. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to treatment. A pregnancy test is not required for registration. Women who have not menstruated for more than 2 years will be considered postmenopausal, thus not of childbearing potential.
  13. ECOG performance score 0, 1 or 2.
  14. Weight ≥ 50 kg because there is limited experience with dasatinib in subjects weighing less than 50 kg.
  15. ≥13 years of age Minors will be required to sign an assent document prior to treatment.
  16. Subjects must be able to swallow whole tablets.
  17. Subjects must be informed of the investigational nature of the study and provide written, informed consent and authorization to release protected health information using a document(s) approved by the investigator's institution.
  18. A paraffin block, either from a previous surgery or recent biopsy, should be available for correlative studies. If a block of tumor is not available, at least 8 unstained slides of tumor sample, 1 H&E and three (3) 15 micron-thick sections in an eppendorf tube for DNA extraction from a representative portion of the sarcoma may be substituted after discussion with and approval from the study Principal Investigator.

Exclusion Criteria:

  1. Subjects who are curable by conventional multidisciplinary management.
  2. Subjects with symptomatic central nervous system metastasis.
  3. Women who are pregnant or nursing/breastfeeding.
  4. History of significant bleeding disorder unrelated to cancer, including:

    • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
    • Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
  5. Subjects currently taking medications that inhibit platelet function (i.e., aspirin, dipyridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, and any non-steroidal anti-inflammatory drug) because of a potential increased risk of bleeding from dasatinib.
  6. Subjects currently taking anticoagulants (warfarin, heparin/low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, enoxaparin]) because of a potential increased risk of bleeding from dasatinib.
  7. Diagnosis of unstable angina or myocardial infarction within 6 months of study entry.
  8. Subjects currently taking one or more of the following drugs that are generally accepted to have a risk of causing Torsades de Pointes:

    • Quinidine, procainamide, disopyramide
    • Amiodarone, sotalol, ibutilide, dofetilide
    • Erythromycins, clarithromycin
    • Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
    • Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
  9. Diagnosed or suspected congenital long QT syndrome.
  10. Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec) within 30 days prior to study registration.
  11. Subjects unable or unwilling to suspend treatment with bisphosphonates for at least the first 8 weeks of treatment with study drug because of the risk of hypocalcemia caused by dasatinib.
Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Sarcoma Alliance for Research through Collaboration
Sarcoma Alliance for Research through Collaboration
Bristol-Myers Squibb
Principal Investigator: Scott Schuetze, MD, PhD University of Michigan
Sarcoma Alliance for Research through Collaboration
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP